Structure Therapeutics Inc. (GPCR)

Pharmaceutical Preparations · market cap $2.6B · as of 2026-07-11

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-11-05 (est.)

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Structure Therapeutics (GPCR) is a clinical-stage pharmaceutical company with a market cap of ~$11.8B and two Phase 2 obesity assets: GSBR-1290 and Aleniglipron. The company carries $316M in cash, no revenue, and is burning ~$141M/year on R&D. The next major binary is estimated Phase 2 data for Aleniglipron around September 15, 2026.

The catalyst path

2026-11-05 (est.)Earningsimp 5/10

Pipeline

Asset	Phase	Indication
GSBR-1290	Phase 2	Overweight or Obesity
Aleniglipron	Phase 2	Obesity, Overweight, or Chronic Weight Management

Price & technical context

3-month

-45.8%

6-month

-42.2%

12-month

+3.5%

52-wk range

$26.04–$93.79

vs 50-day MA

-35.8%

vs 200-day MA

-46.0%

Realized vol

92.8%

Max drawdown

-69.1%

Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for GPCR (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 2 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.